An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Reads0
Chats0
TLDR
The standard of care (SOC) therapy for patients with chronic hepatitis C virus (HCV) infection has been the use of both peginterferon (PegIFN) and ribavirin (RBV) as mentioned in this paper.About:
This article is published in Hepatology.The article was published on 2011-10-01 and is currently open access. It has received 1117 citations till now. The article focuses on the topics: Boceprevir & Telaprevir.read more
Citations
More filters
Journal ArticleDOI
Management algorithm for genotype 1 hepatitis C virus
TL;DR: This article aims to provide a general framework with algorithms to guide initial management decisions for HCV genotype 1 infection, the most commonly found genotype, based on therapies approved as of 2013.
Journal ArticleDOI
Age-based screening recommendations for hepatitis C virus infection.
Susan A. Emerson,Thomas Moreau +1 more
TL;DR: Anyone born between 1945 and 1965 is recognized as an independent risk factor for HCV, which means that anyone born between those years should receive a single anti-HCV screening test performed at the earliest clinical opportunity.
Journal ArticleDOI
Estudio de utilización de boceprevir y telaprevir para el tratamiento de la hepatitis C crónica
P. Marrero-Álvarez,I. Gil-Gómez,Emilio Monte-Boquet,L. Lorente-Fernández,José Luis Poveda-Andrés +4 more
TL;DR: Analizar el grado de cumplimiento de las recomendaciones de la Agencia Espanola de Medicamentos y Productos Sanitarios para la utilizacion of boceprevir y telaprevir en pacientes con HCC en un hospital de tercer nivel se determino si se efectuaban las reglas de suspension del tratamiento por inefectividad.
Journal ArticleDOI
Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy.
Takeshi Nishimura,Kanji Yamaguchi,Hiroaki Hashimoto,Toshihisa Niimi,Chihiro Yokomizo,Hideki Fujii,Masahito Minami,Masafumi Sakamoto,Naoki Ohnish,Yasuyuki Nagao,Mika Okita,Atsushi Umemura,Toshihide Shima,Takeshi Okanoue,Yoshito Itoh +14 more
TL;DR: Little is known about the appropriate use of peginterferon‐α-2b (PEG IFN‐α‐2b) or ribavirin (RBV) in genotype 1 chronic hepatitis C patients with complete early virological response (cEVR), but females, especially the older, are known to experience inferior treatment outcomes.
Journal ArticleDOI
Hereditary hemochromatosis gene mutations in patients with myocardial infarction
TL;DR: No association was found between the HFE gene mutation for HH and myocardial infarction in the population of eastern Slavonia.
References
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Dongliang Ge,Jacques Fellay,Alexander J. Thompson,Jason Simon,Kevin V. Shianna,Thomas J. Urban,Erin L. Heinzen,Ping Qiu,Arthur H. Bertelsen,Andrew J. Muir,Mark S. Sulkowski,John G. McHutchison,David Goldstein +12 more
TL;DR: It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
Journal ArticleDOI
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis,Sette H,Timothy R. Morgan,Balan,Moisés Diago,Patrick Marcellin,G. Ramadori,Henry C. Bodenheimer,David I. Bernstein,Mario Rizzetto,Stefan Zeuzem,Paul J. Pockros,A. Lin,Andrew M. Ackrill +13 more
TL;DR: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.
Journal ArticleDOI
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more
TL;DR: Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.
Related Papers (5)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more